Latest Period
Q4 2025
CUSIP: 74019P207
Latest Period
Q4 2025
Institutions Reporting
67
Shares (Excl. Options)
15,096,207
Price
$4.16
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
Latest holder context comes from 67 institutions filings for Q4 2025.
What is CUSIP 74019P207?
CUSIP 74019P207 identifies DTIL - PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Open recent reporting periods for CUSIP 74019P207:
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Octagon Capital Advisors LP | 10% | $9,570,073 | 2,328,485 | Octagon Capital Advisors LP | 31 Dec 2025 | |||
| Aberdeen Group plc | 8.9% | $8,896,588 | 2,138,603 | Aberdeen Group plc | 31 Dec 2025 | |||
| Empery Asset Management, LP | 7.6% | -24% | $10,828,834 | -$1,808,961 | 1,968,879 | -14% | Empery Asset Management, LP | 31 Mar 2026 |
| Bleichroeder LP | 8.2% | -15% | $7,809,000 | +$3,390,750 | 1,900,000 | +77% | Bleichroeder LP | 31 Dec 2025 |
| Readout Capital, LP | 9.4% | +5.6% | $4,980,934 | +$829,645 | 1,119,311 | +20% | Matthew Smith | 30 Jun 2025 |
| Lynx1 Capital Management LP | 4.1% | -52% | $4,084,982 | -$200,087 | 993,913 | -4.7% | Lynx1 Capital Management LP | 31 Dec 2025 |
| NOVARTIS PHARMA AG | 3.7% | -34% | $1,840,435 | 413,581 | 0% | Novartis Pharma AG | 30 Jun 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 3.7% | $2,165,312 | 406,250 | Highbridge Capital Management, LLC | 31 Mar 2025 | |||
| Weinstein Benjamin | 5.2% | $2,107,956 | 395,489 | Weinstein Benjamin | 18 Mar 2025 |
As of 31 Dec 2025, 67 institutional investors reported holding 15,096,207 shares of PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL). This represents 59% of the company’s total 25,804,443 outstanding shares.
The largest institutional shareholders of PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 8.5% | 2,194,635 | 0% | 8.1% | $9,129,682 |
| Aberdeen Group plc | 8.3% | 2,138,603 | 0.01% | $8,896,588 | |
| Octagon Capital Advisors LP | 7.4% | 1,917,995 | 1% | $7,978,859 | |
| Bleichroeder LP | 6.4% | 1,662,500 | +55% | 1.2% | $6,916,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | 4.1% | 1,066,050 | +497% | 0.12% | $4,434,768 |
| Lynx1 Capital Management LP | 3.9% | 993,913 | -4.7% | 0.84% | $4,134,678 |
| VANGUARD GROUP INC | 3.5% | 906,782 | +84% | 0% | $3,772,213 |
| Alyeska Investment Group, L.P. | 3.1% | 798,000 | 0.01% | $3,319,680 | |
| Driehaus Capital Management LLC | 3.1% | 787,700 | 0.02% | $3,276,832 | |
| SPHERA FUNDS MANAGEMENT LTD. | 1.5% | 396,116 | 0.34% | $1,647,843 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 326,477 | +66% | 0% | $1,358,144 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 225,657 | +106% | 0% | $938,763 |
| BlackRock, Inc. | 0.65% | 168,331 | +71% | 0% | $700,256 |
| TWO SIGMA INVESTMENTS, LP | 0.54% | 139,531 | +68% | 0% | $580,449 |
| MORGAN STANLEY | 0.39% | 99,805 | +853% | 0% | $415,189 |
| 683 Capital Management, LLC | 0.38% | 97,085 | 0.03% | $403,874 | |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.36% | 93,306 | +67% | 0% | $388,150 |
| NORTHERN TRUST CORP | 0.34% | 86,464 | +127% | 0% | $359,690 |
| TWO SIGMA ADVISERS, LP | 0.32% | 83,443 | +60% | 0% | $347,123 |
| MARSHALL WACE, LLP | 0.27% | 70,915 | 0% | $295,004 | |
| Quarry LP | 0.26% | 68,311 | +15% | 0.07% | $284,174 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.26% | 66,581 | 0% | $276,977 | |
| Quadrature Capital Ltd | 0.24% | 62,129 | +345% | 0% | $258,457 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.24% | 61,901 | 0% | 0.01% | $257,508 |
| UBS Group AG | 0.24% | 61,332 | +151% | 0% | $255,141 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 190 | $1,047 | $5.50 | 3 | |
| 2025 Q4 | 15,096,207 | $62,794,720 | +$33,303,415 | $4.16 | 67 |
| 2025 Q3 | 4,649,562 | $25,664,758 | +$1,234,800 | $5.52 | 54 |
| 2025 Q2 | 4,437,938 | $18,638,020 | +$2,152,791 | $4.20 | 51 |
| 2025 Q1 | 3,786,321 | $18,062,451 | +$340,769 | $4.77 | 47 |
| 2024 Q4 | 3,859,340 | $14,708,103 | -$4,075,765 | $3.81 | 51 |
| 2024 Q3 | 3,323,629 | $29,812,914 | +$1,425,206 | $8.96 | 50 |
| 2024 Q2 | 3,161,323 | $30,774,875 | -$108,215 | $9.73 | 45 |
| 2024 Q1 | 3,155,622 | $42,757,614 | +$42,755,553 | $13.56 | 40 |